AU2020100641A4 - Quadruple Regime using Azithromycin 500mg daily plus Vitamin C gram twice daily plus Zinc 500mg daily plus Low-dose Aspirin 100mg daily for 12 weeks to be used as prophylaxis to prevent COVID-19 Virus / Corona Virus / SARS COVID 2 Virus infection in Nursing home / aged care population in Illawarra Region NSW Australia. - Google Patents

Quadruple Regime using Azithromycin 500mg daily plus Vitamin C gram twice daily plus Zinc 500mg daily plus Low-dose Aspirin 100mg daily for 12 weeks to be used as prophylaxis to prevent COVID-19 Virus / Corona Virus / SARS COVID 2 Virus infection in Nursing home / aged care population in Illawarra Region NSW Australia. Download PDF

Info

Publication number
AU2020100641A4
AU2020100641A4 AU2020100641A AU2020100641A AU2020100641A4 AU 2020100641 A4 AU2020100641 A4 AU 2020100641A4 AU 2020100641 A AU2020100641 A AU 2020100641A AU 2020100641 A AU2020100641 A AU 2020100641A AU 2020100641 A4 AU2020100641 A4 AU 2020100641A4
Authority
AU
Australia
Prior art keywords
daily
virus
covid
daily plus
plus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2020100641A
Inventor
Vaidyanathan Balasubramaniam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trustee for The North Coast Rehab Services Trust
Original Assignee
Trustee for The North Coast Rehab Services Trust
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trustee for The North Coast Rehab Services Trust filed Critical Trustee for The North Coast Rehab Services Trust
Priority to AU2020100641A priority Critical patent/AU2020100641A4/en
Application granted granted Critical
Publication of AU2020100641A4 publication Critical patent/AU2020100641A4/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Abstract The present invention describes compositions comprising azithromycin, vitamin C, zinc and acetylsalicylic acid (Aspirin) for the treatment of fever; cough; diarrhoea and flu like symptoms.
AU2020100641A 2020-04-27 2020-04-27 Quadruple Regime using Azithromycin 500mg daily plus Vitamin C gram twice daily plus Zinc 500mg daily plus Low-dose Aspirin 100mg daily for 12 weeks to be used as prophylaxis to prevent COVID-19 Virus / Corona Virus / SARS COVID 2 Virus infection in Nursing home / aged care population in Illawarra Region NSW Australia. Ceased AU2020100641A4 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020100641A AU2020100641A4 (en) 2020-04-27 2020-04-27 Quadruple Regime using Azithromycin 500mg daily plus Vitamin C gram twice daily plus Zinc 500mg daily plus Low-dose Aspirin 100mg daily for 12 weeks to be used as prophylaxis to prevent COVID-19 Virus / Corona Virus / SARS COVID 2 Virus infection in Nursing home / aged care population in Illawarra Region NSW Australia.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2020100641A AU2020100641A4 (en) 2020-04-27 2020-04-27 Quadruple Regime using Azithromycin 500mg daily plus Vitamin C gram twice daily plus Zinc 500mg daily plus Low-dose Aspirin 100mg daily for 12 weeks to be used as prophylaxis to prevent COVID-19 Virus / Corona Virus / SARS COVID 2 Virus infection in Nursing home / aged care population in Illawarra Region NSW Australia.

Publications (1)

Publication Number Publication Date
AU2020100641A4 true AU2020100641A4 (en) 2020-06-04

Family

ID=70847888

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020100641A Ceased AU2020100641A4 (en) 2020-04-27 2020-04-27 Quadruple Regime using Azithromycin 500mg daily plus Vitamin C gram twice daily plus Zinc 500mg daily plus Low-dose Aspirin 100mg daily for 12 weeks to be used as prophylaxis to prevent COVID-19 Virus / Corona Virus / SARS COVID 2 Virus infection in Nursing home / aged care population in Illawarra Region NSW Australia.

Country Status (1)

Country Link
AU (1) AU2020100641A4 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3932409A1 (en) * 2020-06-29 2022-01-05 Consejo Superior de Investigaciones Científicas (CSIC) Compounds for the treatment and prevention of viral infections caused by coronaviruses

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3932409A1 (en) * 2020-06-29 2022-01-05 Consejo Superior de Investigaciones Científicas (CSIC) Compounds for the treatment and prevention of viral infections caused by coronaviruses
WO2022002789A1 (en) * 2020-06-29 2022-01-06 Consejo Superior De Investigaciones Cientificas (Csic) Compounds selected from clarithromycin and lexithromycin for the treatment and prevention of viral infections caused by coronaviruses

Similar Documents

Publication Publication Date Title
A Puertollano et al. Dietary antioxidants: immunity and host defense
GEP20074176B (en) Topical pharmaceutical compositions comprising proanthocyanidins for the treatment of dermatitis
Geoghegan et al. Inhibitory effect of quercetin on periodontal pathogens in vitro
Suttajit Advances in nutrition support for quality of life in HIV+/AIDS
MX354047B (en) SPRAY-DRIED <i>LACTOBACILLUS</i> STEMS / CELLS AND THE USE OF SAME AGAINST <i>HELICOBACTER PYLORI.
JOP20220179A1 (en) N4-hydroxycytidine and derivatives and anti-viral uses related thereto
WO2006112714A3 (en) Uronic acid and probiotics
BRPI1007379B8 (en) pharmaceutical compositions for the treatment or prevention of oral infections by e. coli
WO2009092383A3 (en) Products and methods to prevent infection
HUP0301815A2 (en) Mono and disaccharide-based pharmaceutical composition for infections and other diseases and prophylactic and therapeutic treatment
PL1940248T3 (en) Use of a nutritional formulation for promoting catch-up growth
BR112018014545A2 (en) probiotics for use as anti-inflammatory agents in the oral cavity
AU2020100641A4 (en) Quadruple Regime using Azithromycin 500mg daily plus Vitamin C gram twice daily plus Zinc 500mg daily plus Low-dose Aspirin 100mg daily for 12 weeks to be used as prophylaxis to prevent COVID-19 Virus / Corona Virus / SARS COVID 2 Virus infection in Nursing home / aged care population in Illawarra Region NSW Australia.
MX2017016028A (en) Formulations for the treatment of disorders of the mouth, throat and respiratory tract.
CO2022013143A2 (en) Cutibacterium acnes strain and medical uses thereof
BR112017017241B8 (en) Purified soda blend compositions of plant origin
HUP0300732A2 (en) Plant-derived and synthetic phenolic compounds and plant extracts, effective in the treatment and prevention of chlamydial infections
PT1796702E (en) Use of lavender oil for the prophylaxis and treatment of somatization disorders and posttraumatic stress disorder
EP1911455B1 (en) Topical vaginal pharmaceutical compositions
Deshpande et al. Probiotic Bacteriotherapy and Its Oral Health Perspective
WO2022011271A3 (en) Probiotics for use in the prevention or treatment of illness and/or symptoms associated with coronaviruses
MX2022011596A (en) Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection.
Bhunia Bioengineered probiotics–A solution to broaden probiotics efficacy
Dalvi et al. Study of vitamins in pulmonary tuberculosis
Ko et al. Analysis of periodontal pathogens in care facilities for the elderly with dementia

Legal Events

Date Code Title Description
FGI Letters patent sealed or granted (innovation patent)
MK22 Patent ceased section 143a(d), or expired - non payment of renewal fee or expiry